LONDON, Sept 12 (Reuters) - GlaxoSmithKline Plc is creating a new cancer-focused research and development group, marking a realignment of its R&D machine, the world’s second largest drugmaker said on Friday.
LONDON, Sept 12 (Reuters) - GlaxoSmithKline Plc is creating a new cancer-focused research and development group, marking a realignment of its R&D machine, the world’s second largest drugmaker said on Friday.